Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|4|616-624

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.4, 2014-02, pp. : 616-624

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting ErbB Receptors in High-Grade Glioma

By  

Current Pharmaceutical Design, Vol. 17, Iss. 23, 2011-08 ,pp. : 2468-2487

Bentham Science Publishers

Access to resources Recommend Favorite

The ErbB Receptors and their Ligands in Cancer: An Overview

By  

Current Drug Targets, Vol. 6, Iss. 3, 2005-05 ,pp. : 243-257

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions

By  

Current Pharmaceutical Design, Vol. 20, Iss. 4, 2014-02 ,pp. : 601-602

Bentham Science Publishers

Access to resources Recommend Favorite

Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer

By  

Current Cancer Drug Targets, Vol. 14, Iss. 9, 2014-11 ,pp. : 775-793

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis

By  

Current Pharmaceutical Design, Vol. 20, Iss. 30, 2014-09 ,pp. : 4899-4905

Bentham Science Publishers

Access to resources Recommend Favorite